版权说明 操作指南
首页 > 成果 > 详情

Elabela-APJ axis: a novel therapy target for cardiovascular diseases

认领
导出
下载 Link by DOI
反馈
分享
QQ微信 微博
成果类型:
期刊论文
作者:
Lanfang Li;Qionglin Zhou;Xiaoxiao Li;Linxi Chen*
通讯作者:
Linxi Chen
作者机构:
[Li Lanfang; Zhou Qionglin; Li Xiaoxiao; Chen Linxi] Institute of Pharmacy and Pharmacology, University of South China, Learning Key Laboratory for Pharmacoproteomics
[Li Lanfang; Zhou Qionglin; Li Xiaoxiao; Chen Linxi] Hunan Province Cooperative Innovation Center for Molecular Target New Drug Study, Hengyang, 421001
通讯机构:
[Linxi Chen] 1
语种:
英文
期刊:
生物化学与生物物理学报
ISSN:
1672-9145
年:
2017
卷:
49
期:
11
页码:
1042-1043
基金类别:
This work was supported by the grants from the National Natural Science Foundation of China (No. 81670265), the Natural Science Foundation of Hunan Province (No. 2017JJ2227), and the Cooperative Innovation Center for Molecular Target New Drug Study Undergraduate Innovative Experimental Project in University of South China (0223-0002-00015).
机构署名:
本校为第一且通讯机构
院系归属:
药学与生物科学学院
摘要:
The apelin receptor gene, also known as APJ or angiotensin receptor-like 1, was first cloned in 1993. APJ has strong sequence homology with the angiotensin II receptor (AT1); 54% for intrans membrane domains and 31% for the entire sequence. Nevertheless, APJ does not bind with angiotensin II. In 1998, Apelin, the first endogenous ligand for APJ, was identified in bovine stomach extracts. Both apelin and APJ are widely expressed in various tissues including the heart, brain, limbs, retin...

反馈

验证码:
看不清楚,换一个
确定
取消

成果认领

标题:
用户 作者 通讯作者
请选择
请选择
确定
取消

提示

该栏目需要登录且有访问权限才可以访问

如果您有访问权限,请直接 登录访问

如果您没有访问权限,请联系管理员申请开通

管理员联系邮箱:yun@hnwdkj.com